This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Rubella virus vaccine is a vaccine used to prevent Rubella.

Brand Names
M-M-R II, Proquad
Generic Name
Rubella virus vaccine
DrugBank Accession Number
DB10317
Background

Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Rubella virus (vaccine strain RA27/3) live antigen
  • Rubella virus live antigen, A
  • Rubella virus strain Wistar RA 27/3 live (attenuated) antigen
  • Rubella virus strain Wistar RA 27/3 live antigen
  • Rubella virus vaccine live (Wistar RA 27-3 strain)
  • Rubella virus vaccine live attenuated (Wistar RA27/3 strain)
  • Rubella virus vaccine,live
  • Rubella, live attenuated
  • Rubivirus rubella virus Wistar RA 27/3 whole

Pharmacology

Indication

Rubella virus vaccine is used to prevent rubella in combination with other virus vaccines, such as the mumps and measles virus vaccine.1,2,3

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Altretamine.
AmantadineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Amantadine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Meruvax II
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Rubella Virus Vacc Live Att Freez Dried InjPowder, for solution1000 unit / vialSubcutaneousIaf Biovac Inc.1991-12-311997-08-20Canada flag
Rubella Virus Vaccine Live Dried AttenuatedPowder, for solution1000 unit / 0.5 mLSubcutaneousAventis Pasteur Limited1983-12-312000-04-07Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousA-S Medication Solutions1971-04-21Not applicableUS flag
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousPhysicians Total Care, Inc.1996-08-072012-06-30US flag
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Llc1971-04-21Not applicableUS flag
M-M-R IIRubella virus vaccine (1000 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.1979-12-31Not applicableCanada flag
M-M-R II VACCINERubella virus vaccine (1000 CCID50/0.5mL) + Measles virus vaccine live attenuated (1000 CCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 CCID50/0.5mL)Injection, powder, for solutionSubcutaneousMSD PHARMA (SINGAPORE) PTE. LTD.1988-06-24Not applicable
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Merck Sharp & Dohme B.V.2021-02-10Not applicableEU flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Merck Sharp & Dohme B.V.2021-02-10Not applicableEU flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Injection, powder, for suspensionIntramuscular; SubcutaneousMerck Sharp & Dohme B.V.2021-02-10Not applicableEU flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Merck Sharp & Dohme B.V.2021-02-10Not applicableEU flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Merck Sharp & Dohme B.V.2021-02-10Not applicableEU flag

Categories

ATC Codes
J07BD53 — Measles, combinations with rubella, live attenuatedJ07BD54 — Measles, combinations with mumps, rubella and varicella, live attenuatedJ07BD52 — Measles, combinations with mumps and rubella, live attenuatedJ07BJ01 — Rubella, live attenuatedJ07BJ51 — Rubella, combinations with mumps, live attenuatedJ07BD51 — Measles, combinations with mumps, live attenuated
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
52202H034Z
CAS number
Not Available

References

General References
  1. TITCK Product Information: R-VAC (rubella vaccine, live, attenuated) for subcutaneous injection [Link]
  2. DailyMed: Proquad (measles, mumps, rubella, and varicella live vaccine) lyophilized powder for injection [Link]
  3. FDA Approved Drug Products: PRIORIX (Measles, Mumps, and Rubella Vaccine, Live), suspension for subcutaneous injection [Link]
PubChem Substance
347910496
RxNav
9486

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionChildren / Death / Measles Vaccination / Morbidity / Non-specific/Heterologous Effects of Vaccines / Oral Polio Vaccine1
4Active Not RecruitingPreventionHepatitis A / Measles / Varicella1
4CompletedNot AvailableRheumatoid Arthritis, Juvenile1
4CompletedDiagnosticDiphtheria / Measles / Pertussis / Tetanus1
4CompletedPreventionAdverse Event Following Immunization / Measles / Mumps / Rubella1
4CompletedPreventionBCG Infection / Immune Responses / Vaccine Reaction1
4CompletedPreventionChickenpox / Hepatitis A / Measles / Mumps / Rubella1
4CompletedPreventionDeath / Vaccines1
4CompletedPreventionHepatitis A Virus1
4CompletedPreventionHepatitis A / Measles / Mumps / Rubella1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionSubcutaneous
Injection, powder, lyophilized, for suspensionSubcutaneous
Powder, for solutionSubcutaneous
Injection, powder, for solutionSubcutaneous1000 CCID50/0.5mL
Injection, powder, for suspensionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous
Liquid; powder, for solutionSubcutaneous
Injection, powder, for solutionSubcutaneous
Kit; powder, for solutionIntramuscular; Subcutaneous
Injection, solutionIntramuscular; Subcutaneous
Injection, powder, for solutionIntramuscular; Subcutaneous
Injection, powder, for solutionIntramuscular; Subcutaneous1000 TCID50/0.5ml
Injection
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous1000 CCID50
Powder, for solutionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for suspensionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for solutionSubcutaneous3 log10 tcid50/0.5mL
InjectionSubcutaneous
Powder, for solutionSubcutaneous1000 unit / vial
Powder, for solutionSubcutaneous1000 unit / 0.5 mL
InjectionSubcutaneous
Injection, powder, lyophilized, for suspensionSubcutaneous
Solution
Injection, powder, lyophilized, for suspension
Powder
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:03 / Updated at June 24, 2022 08:21